A vaccine which triggers the immune
system to attack the most common type of lung cancer has shown promise in early
clinical trials, say researchers.
Tests on 148 patients, reported in the Lancet Oncology, showed that
adding the vaccine to chemotherapy slowed the cancer's progression.However, its effect on overall survival was limited and further trials are now needed.
Cancer Research UK said there were many unanswered questions.
Vaccines for cancer use the same principles as vaccines against infection - training the body's own immune system. However, instead of protecting against measles or seasonal flu, these vaccines attack tumours growing in the body.
9:59 AM | 0
komentar | Read More